Advertisement

Cancer Therapy pp 147-161 | Cite as

Chemical Xenogenization of Experimental Tumors by Antineoplastic Drugs

  • P. Puccetti
  • U. Grohmann
  • R. Bianchi
  • L. Binaglia
  • M. L. Belladonna
  • M. Allegrucci
  • M. C. Fioretti
Conference paper
Part of the NATO ASI Series book series (volume 75)

Abstract

The antigenic phenotype of experimental tumors can be modified through procedures that either directly -and rather transiently, as a rule- affect the membrane structures of the cell or involve stable, often hereditary, changes in the cell biology (e.g., the genetic code). The term of chemical xenogenizationwas introduced by our group to indicate the appearance of tumor-associated transplantation antigens in murine tumors subjected to chemical treatment, and thus rendered antigenically foreign to the host of origin (Puccetti et al., 1987). Bonmassar et al. (1970) had indeed found that murine leukemia cells, on repeated in vivo exposure to the antitumor agent dacarbazine, would become increasingly immunogenic, eventually acquiring a degree of foreignness capable of resulting in tumor cell rejection by the histocompatible host.

Keywords

Parental Cell Cancer Immunol Parental Tumor Tumor Variant Murine Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Apt D, Schreck J, Altevogt P: Endogenous retroviral env genes after N-methyl-N’-nitro- N-nitrosoguanidine treatment of mouse tumor cells: stable DNA amplifications and rearrangement. Cancer Res 49: 3966–3971, 1989.PubMedGoogle Scholar
  2. Bianchi R, Citti L, Beghetti R, Romani L, D’lncalci M, Puccetti P, Fioretti MC: O6- Methylguanine-DNA methyltransferase activity and induction of novel immunogenicity in murine tumor cells treated with methylating agents. Cancer Chemother Pharmacol 29: 277–282, 1992a.PubMedCrossRefGoogle Scholar
  3. Bianchi R, Fioretti MC, Grohmann U, Binaglia L, Romani L, Puccetti P: Tumor-specific L3T4+ and Lyt-2+ lymphocytes in mice primed to xenogenized tumor variants. Int J Immunopharmac 14: 915–921, 1992.CrossRefGoogle Scholar
  4. Bianchi R, Fioretti MC, Romani L, Grohmann U, Cenci E, Puccetti P: T-cell subsets, IFN-ϒ production and efferent specificity in anti-parental tumor immunity induced by mouse sensitization with xenogenized variant cells. Int J Cancer, 46: 653–657, 1990.PubMedCrossRefGoogle Scholar
  5. Bianchi R, Romani L, Puccetti P, Fioretti MC: Induction of tumor suppression and delayed- type footpad reaction by transfer of lymphocytes sensitized to a xenogenized tumor variant. Int J Cancer 42: 71–75, 1988.PubMedCrossRefGoogle Scholar
  6. Bianchi R, Romani L, Puccetti P, Fioretti MC: Inhibition of murine lymphoma growth by adoptive transfer of lymphocytes sensitized to a xenogenized tumor variant. Int J Cancer 40: 7–11, 1987.PubMedCrossRefGoogle Scholar
  7. Boon T: Antigenic tumor cell variants obtained with mutagens. Adv Cancer Res 39: 121–151, 1983.PubMedCrossRefGoogle Scholar
  8. Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A: Antigenic changes of L1210 leukemia in mice treated with 5-(3–3’-dimethyl-1-triazeno)imidazole-4-carboxamide. Cancer Res 32: 1446–1450, 1972.PubMedGoogle Scholar
  9. Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A: Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug. Proc Nat Acad Sei (Wash) 66: 1089–1095, 1970.CrossRefGoogle Scholar
  10. Contessa AR, Giampietri A, Bonmassar A, Goldin A: Increased immunogenicity of L1210 leukemia following short-term exposure to 5(3,3’-dimethyl-1-triazeno) imidazole-4- carboxamide (DHC) in vivo or in vitro. Cancer Immunol Immunother 7: 71–76, 1979.CrossRefGoogle Scholar
  11. De Plaen E, Lurquin C, Van Pel A, Mariame B, Szikora J-P, Wölfel T, Sibille C, Chomez P, Boon T: Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tumantigen P91A and Identification of the tum- mutation. Proc Nat Acad Sei (Wash) 85: 2274–2278, 1988.CrossRefGoogle Scholar
  12. Fioretti MC, Nardelli B, Bianchi R, Nisi C, Sava G: Antigenic changes of a murine lymphoma by in vivo treatment with triazene derivatives. Cancer Immunol Immunother 11: 283–286, 1981.CrossRefGoogle Scholar
  13. Fioretti MC, Romani L, Bonmassar A, Taramelli D: Appearance of strong transplantation antigens in non-immunogenic lymphoma following drug treatment in vivo. J Immunopharmacol 2: 189–212, 1980.PubMedGoogle Scholar
  14. Fuschiotti P, Fioretti MC, Romani L, Puccetti P: Lack of correlation between DNA- methylating activity and appearance of the immunogenic phenotype in clones of a murine lymphoma treated with mutagens. Cancer Immunol Immunother 29: 139–143, 1989.PubMedCrossRefGoogle Scholar
  15. Grohmann U, Puccetti P, Romani L, Binaglia L, Bianchi R, Belladonna ML, Ullrich SJ, Appella E, Fioretti MC: Immunogenic tumor variants induced by drug treatment of the L5178Y lymphoma: search for serologically defined antigens at the clonal level. Int J Cancer 52: 372–377, 1992.PubMedCrossRefGoogle Scholar
  16. Grohmann U, Romani L, Binaglia L, Fioretti MC, Puccetti P: Intrasplenic immunization for induction of humoral and cell-mediated immunity to nitrocellulose-bound antigen. J Immunol Methods 137: 9–16, 1991.PubMedCrossRefGoogle Scholar
  17. Grohmann U, Ullrich S, Mage MG, Appella E, Fioretti MC, Puccetti P, Romani L: Identification and immunogenic properties of an 80 kDa surface antigen on a drug-treated tumor variant: relationship to MuLV gp70. Eur J Immunol 20: 629–636, 1990.PubMedCrossRefGoogle Scholar
  18. Jacquemin PC: Expression of type C viral glycoproteins on P815 cells: higher expression pf Mr 70,000 glycoprotein-containing glycoprotein on immunogenic variants. Cancer Res 42: 3828–3836, 1982.PubMedGoogle Scholar
  19. Keene JA, Forman J: Helper activity is required for in vivo generation of cytotoxic T lymphocytes. J Exp Med 155: 768–782, 1982.PubMedCrossRefGoogle Scholar
  20. Nardelli B, Contessa AR, Romani L, Sava G, Nisi C, Fioretti MC: Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazene-derivatives. Cancer Immunol Immunother 16: 157–161, 1984.PubMedCrossRefGoogle Scholar
  21. Nicolin A, Bini A, Coronetti E, Goldin A: Cellular immune response to a drug treated L5178Y lymphoma subline. Nature 251: 654–655, 1974.PubMedCrossRefGoogle Scholar
  22. Nicolin A, Spreafico F, Bonmassar E, Goldin A: Antigenic changes of L5178Y lymphoma after treatment with 5-(3,3 dimethyl-1-triazeno)imidazole-4-carboxamide in vivo. J Natl Cancer Inst 56: 89–93, 1976.PubMedGoogle Scholar
  23. Puccetti P, Bianchi R, Romani L, Cenci E, Fioretti MC: Delayed-type hypersensitivity to tumor antigens co-expressed with immunogenic determinants induced by xenogenization. Int J Cancer 43: 279–284, 1989.PubMedCrossRefGoogle Scholar
  24. Puccetti P, Romani L, Fioretti MC: Chemical xenogenization of experimental tumors. Cancer Metast Rev 6: 93–111, 1987.CrossRefGoogle Scholar
  25. Puccetti P, Romani L, Grohmann U, Bianchi R, Fuschiotti P, Allegrucci M, Fioretti MC: Xenogenization of experimental tumors by triazene derivatives. In: Giraldi T, Connors TA, Cartei G (eds) Tiazenes, Plenum Press, New York, pp 79–89, 1990.CrossRefGoogle Scholar
  26. Riccardi C, Fioretti MC, Giampietri A, Puccetti P, Goldin A: Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo. Transplantation 25: 63–68, 1978.PubMedCrossRefGoogle Scholar
  27. Romani L, Fioretti MC, Bonmassar E: In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically alterated by 5-(3,3’-dimethyl-1-triazeno) imidazole-4-carboxamide in vivo. Transplantation 28: 218–222, 1979.PubMedCrossRefGoogle Scholar
  28. Romani L, Grohmann U, Fazioli F, Puccetti P, Mage MG, Fioretti MC: Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens. Cancer Immunol Immunother 26: 48–54, 1988.PubMedCrossRefGoogle Scholar
  29. Romani L, Grohmann U, Puccetti P, Rossi MA, Fioretti MC: Cell-mediated immunity to chemically xenogenized tumors. V. Failure of novel antigens to increase the frequency of tumor-specific cytotoxic T cells. Int J Immunopharmac 12: 743–749, 1990.CrossRefGoogle Scholar
  30. Romani L, Puccetti P, Fioretti MC, Mage MG: Humoral response against murine lymphoma cells xenogenized by drug treatment in vivo. Int J Cancer 36: 225 - 231, 1985.PubMedCrossRefGoogle Scholar
  31. Romani L, Puccetti P, Grohmann U, Cenci E, Mage MG, Fioretti MC: Cell-mediated immunity to chemically xenogenized tumors. IV. Produetion of lymphokine activity by, and in response to, highly immunogenic cells. Int J Immunopharmac 11: 537–542, 1989.CrossRefGoogle Scholar
  32. Santoni A, Kinney Y, Goldin A: Secondary cytotoxic response in vitro against Moloney lymphoma cells antigenically altered by drug treatment in vivo. J Natl Cancer Inst 60: 109–112, 1978.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • P. Puccetti
    • 1
  • U. Grohmann
    • 1
  • R. Bianchi
    • 1
  • L. Binaglia
    • 1
  • M. L. Belladonna
    • 1
  • M. Allegrucci
    • 1
  • M. C. Fioretti
    • 1
  1. 1.Section of PharmacologyUniversity of PerugiaItaly

Personalised recommendations